Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease

Boehringer Ingelheim

Status: Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Treatments: Drug: Atrovent® inhalets

Study type: Observational

Funder types: Industry

Identifiers

NCT02238158

244.2496

Details and patient eligibility

About

To obtain further information on the tolerability and efficacy of Atrovent® inhalets in long term treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice

Enrollment: 595 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Primarily patients of both gender, older than 40 years, who suffer from Chronic Obstructive Pulmonary Disease
• Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion

Exclusion criteria

• Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® Inhalets

Trial design

595 participants in 1 patient group

Chronic Obstructive Pulmonary Disease

Treatment:

Drug: Atrovent® inhalets